Dr. Jian-Guo Geng, MD, PhD – Associate Professor at University of Michigan

Dr. Geng received his MD and PhD from the Shanghai Medical University and is an Associate Professor at the University of Michigan. He has also held research and faculty positions at major companies and universities including Pharmacia & Upjohn, Shanghai Institutes for Biological Sciences, and the University of Minnesota. Dr. Geng has significant experience developing chemotherapeutic reagents. For example, Dr. Geng has recently developed and licensed novel chemotherapeutic reagent to Sanofi-Aventis. Dr. Geng has published over 70 peer-reviewed papers and is an internationally renowned scientist in the cancer research field.

Dr. Christian Naus, Ph. D. – Professor Emeritus at University of British Columbia

Dr. Christian Naus received a PhD in Anatomy from the University of Western Ontario. He is a member of the Faculty of Medicine at the University of British Columbia where he has served as Department Head and Director of the Life Sciences Institute. He has conducted over 35 years of research in neurobiology and cancer to diagnose disease and develop novel therapeutic strategies. This work has led to numerous collaborations with industry, intellectual property, and the publication of over 175 peer reviewed articles. Dr. Naus has held a Canada Research Chair in Gap Junctions in Neurological Disorders, and is an elected Fellow of the Canadian Academy of Health Sciences.

Dr. Dmitry Temiakov, PhD – Associate Professor at Thomas Jefferson University

Dr. Temiakov received his PhD from the Russian Academy of Science and is an Associate Professor at Thomas Jefferson University. He is a renowned leader in the field of protein production and structural analysis. His research has been published in the world’s most prominent scientific journals. His thesis work focused on plant lectins, and he has been staying abreast of the structural and functional mechanisms underlying medicinal products for over 20 years. Dr. Temiakov is uniquely able to help achieve our milestones, particularly the refinement of MASL to treat cancer and inflammatory disease.